Founded in 2019, Gannex, a wholly-owned company of Ascletis Pharma Inc. (1672.HK), is dedicated to the R&D and commercialization of new drugs in the field of MASH. Gannex has two clinical stage drug candidates against two different targets — FASN and THRβ.
Email：
pr@gannexpharma.com
ir@gannexpharma.com
hr@gannexpharma.com
All contents © Copyright Gannex Pharma Co., Ltd.All Rights Reserved
This site is published by Gannex Pharma Co., Ltd.
which is solely responsible for all site content.
